Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab

The NDA is supported by results from JUPITER-02, a randomized, double-blind, placebo-controlled, multinational multi-center Phase 3 clinical study (NCT03581786) that examined toripalimab in combination with gemcitabine-cisplatin as the first-line treatment of NPC, as well as results from POLARIS-02, a multi-center, open-label, pivotal Phase 2 clinical study (NCT02915432) that evaluated toripalimab as the second-line or later treatment for recurrent or metastatic NPC. Read More

Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab

Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab

Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab

Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
Ads Links by Easy Branches
Play online games for free at games.easybranches.com
Guest Post Services www.easybranches.com/contribute
From Tokyo to New York, Stock Markets Are on a Record-Hitting Spree Around the World
S&P Profit Recovery Revs Up on Big Tech and Strong Consumer

Canada is exploring higher tariffs on Chinese EVs, trade minister says